1Q is January to March, April not included, yeah it's part of first quarter of launch but not fiscal quarter which is what earning swill be based on and Q1 sales don't matter nearly as much as managements view on the future.
MKM Partner's LeCroy: "...would imply Q1 Vascepa sales of approximately $2.2M and Q2 of around $11M. So, while the consensus estimates still appear to be slightly high, LeCroy thinks that with stocking, they still could be attainable..."